Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mega Genomics's Free Cash Flow for the
six
months ended in Dec. 2025 was HK$-16.9 Mil. Mega Genomics's Revenue for the
six
months ended in Dec. 2025 was HK$183.2 Mil. Therefore, Mega Genomics's FCF Margin % for the quarter that ended in Dec. 2025 was -9.21%.
The historical rank and industry rank for Mega Genomics's FCF Margin % or its related term are showing as below:
HKSE:06667'
s FCF Margin % Range Over the Past 10 Years
Min: -8.3 Med: 29.52 Max: 84.33
Current: -4.54
During the past 7 years, the highest FCF Margin % of Mega Genomics was 84.33%. The lowest was -8.30%. And the median was 29.52%.
HKSE:06667's FCF Margin % is ranked worse than 56.65% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.39
vs HKSE:06667: -4.54
The historical data trend for Mega Genomics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06667 vs TMO, DHR, NTRA: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Mega Genomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Genomics FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mega Genomics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mega Genomics (HKSE:06667) has a FCF Margin % of -9.21% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mega Genomics and its competitors. According to the industry distribution chart, Mega Genomics ranks #115 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 56.7%.
Is Mega Genomics' FCF Margin % too high?
Mega Genomics' current FCF Margin % is -9.21%. Based on the distribution chart, Mega Genomics ranks #115 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Mega Genomics ranks #115 out of 203 companies for FCF Margin %. This places Mega Genomics in the lower half of its industry. The industry median FCF Margin % is 0.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
The median FCF Margin % among Medical Diagnostics & Research companies is 0.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mega Genomics and its competitors. For the Medical Diagnostics & Research industry, the median FCF Margin % is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mega Genomics's current FCF Margin % is -9.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current FCF Margin % is -9.21%. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current FCF Margin % is -9.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mega Genomics (HKSE:06667) Overvalued in 2026?
Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued.
The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92.
GuruFocus considers Mega Genomics to be Possible Value Trap.
Key valuation signals for HKSE:06667:
FCF Margin %: -9.21%
GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score
Get the complete analysis for HKSE:06667
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06667 has been successfully added to your 
